© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 22, 2020
Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.
Saad Usmani, MD, reflects on the impact the coronavirus pandemic has had on his practice and the treatment of patients with multiple myeloma overall.
The MAIA & PEGASUS Trial and Managing Patients Receiving DRd
Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.
Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.
Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.